Elevated Maternal Uric Acid during mid gestation may Predict Hypertensive Disorders of Pregnancy: Study

Written By :  Dr. Shravani Dali
Published On 2026-01-28 15:00 GMT   |   Update On 2026-01-28 15:00 GMT
Advertisement

Elevated maternal uric acid levels during early to mid-gestation are independently associated with an increased risk of hypertensive disorders of pregnancy. This association varies by hypertensive disorder of pregnancy subtype and gestational age. Maternal uric acid may serve as a practical biomarker for early risk stratification and for ongoing monitoring of women at risk for hypertensive complications during pregnancy.

Advertisement

A study was conducted to examine the association between maternal serum uric acid measured during gestational weeks 4–24 and the subsequent development of hypertensive disorders of pregnancy in a large Chinese cohort. This historical cohort study included 84,298 singleton pregnancies registered at Shanghai First Maternity and Infant Hospital between 2013 and 2022. Serum uric acid was measured before 24 weeks of gestation. Participants with pre-existing hypertension or incomplete data were excluded. Generalized additive models and multivariable logistic regression analyses were used to assess nonlinear and independent associations between uric acid levels (quartiles and continuous values) and the risks of gestational hypertension, preeclampsia, and overall hypertensive disorders of pregnancy, adjusting for maternal age, pre-pregnancy body mass index, education, and glucose metabolism disorders.

Results showed that uric acid levels were consistently higher among women who later developed hypertensive disorders of pregnancy than in normotensive pregnancies throughout gestational weeks 4–24. Higher uric acid concentrations were consistently associated with an increased risk of hypertensive disorders of pregnancy. The highest uric acid quartile showed the strongest associations with gestational hypertension (1.82, 1.59–2.08), preeclampsia (1.67, 1.48–1.89), and total hypertensive disorders of pregnancy (1.77, 1.61–1.94). Generalized additive model analyses revealed an enhanced relationship between uric acid and hypertensive disorders of pregnancy occurrence from the 4th week to the 24th week of gestation and showed specific patterns for gestational hypertension and preeclampsia, with the predictive strength of maternal uric acid increasing with advancing gestational age.

Elevated maternal uric acid levels in early to mid-gestation were independently related to the risk of hypertensive disorders of pregnancy, with subtype-specific and gestational-age-dependent patterns. Uric acid serves as a practical potential biomarker for early risk stratification and dynamic monitoring of women at risk for hypertensive complications during pregnancy. Elevated maternal uric acid (UA) levels during early to mid-gestation are independently associated with an increased risk of hypertensive disorders of pregnancy (HDP). This association varies by HDP subtype and gestational age. Maternal UA may serve as a practical biomarker for early risk stratification and for ongoing monitoring of women at risk for hypertensive complications during pregnancy.

A study was done to examine association between maternal serum uric acid (UA) measured during gestational 4–24 weeks and the subsequent development of hypertensive disorders of pregnancy (HDP) in a large Chinese cohort. This historical cohort study included 84,298 singleton pregnancies registered at Shanghai First Maternity and Infant Hospital (2013–2022). Serum UA was measured before 24 weeks of gestation. Participants with pre-existing hypertension or incomplete data were excluded. Generalized additive models (GAMs) and multivariable logistic regression analyses were used to assess nonlinear and independent associations between UA levels (quartiles and continuous values) and risks of gestational hypertension (GH), preeclampsia (PE), and overall HDP cases, adjusting for maternal age, pre-pregnancy BMI, education, and glucose metabolism disorders. Results: UA levels were consistently higher among women who later developed HDP than in normotensive pregnancies throughout gestational weeks 4–24. Higher UA concentrations consistently associated with an increased risk of HDP diseases, the top UA quartile showed the strongest associations with GH (1.82, 1.59–2.08), PE (1.67, 1.48–1.89), and total HDP (1.77, 1.61–1.94). GAM analyses revealed enhanced relation of UA to HDP occurrence from the 4th week to 24th week, and showed specific patterns in GH/PE, predictive strength of maternal UA increased with advancing gestational age.
Elevated maternal UA levels in early-to-mid gestation independently related to HDP risk, with subtype-specific and gestational-age–dependent patterns. UA serves as a practical potential biomarker for early risk stratification and dynamic monitoring of women at risk for hypertensive complications.

Reference:

Zou, C., Zhao, R., Liu, X., Yang, Y., Shen, Q., & Du, Q. (2025, December 12). Association of early and mid-pregnancy maternal serum uric acid with hypertensive disorders of pregnancy. Frontiers in Endocrinology, 16, Article 1731576. https://doi.org/10.3389/fendo.2025.1731576


Keywords:

Elevated, Maternal, Uric Acid, during, mid gestation, Predict, Hypertensive, Disorders, Pregnancy, study, Zou, C., Zhao, R., Liu, X., Yang, Y., Shen, Q., & Du, Q.




Tags:    
Article Source : Frontiers in Endocrinology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News